

- Preven Med, 2016, 22(3):193-197, 201. DOI:CNKI:SUN:GXYX.0.2016-03-001.
- [9] 白云骅, 邵忆楠, 杨立清, 等. 国产冻干人用狂犬病疫苗 (Vero 细胞) 上市后安全性观察[J]. 中国疫苗和免疫, 2018, 24(3):319-322.
Bai YY, Shao YN, Yang LQ, et al. Safety observation of domestic lyophilized human rabies vaccine (Vero cells) after marketing[J]. Chin J Vacc Immun, 2018, 24(3): 319-322.
- [10] 石晓娟, 周路平, 周莉薇, 等. 国产 Sabin 株脊髓灰质炎灭活疫苗接种后的安全性调查[J]. 中国疫苗和免疫, 2017, 23(4):383-386. DOI:CNKI:SUN:ZGJM.0.2017-04-006.
Shi XJ, Zhou LP, Zhou LW, et al. Safety investigation of domestic Sabin strain poliomyelitis inactivated vaccine after inoculation[J]. Chin J Vacc Immun, 2017, 23(4): 383-386. DOI:CNKI:SUN:ZGJM.0.2017-04-006.
- [11] 刘小琴, 陈海平, 张振国, 等. Sabin 株脊髓灰质炎灭活疫苗 (Vero 细胞) 上市后的安全性评价[J]. 中国生物制品学杂志, 2019, 32(12):1386-1389. DOI:10.13200/j.cnki.cjb.002918.
Liu XQ, Chen HP, Zhang ZG, et al. Safety evaluation of Sabin poliomyelitis inactivated vaccine (Vero cells) after marketing[J]. Chin J Biolog Chin J Biol, 2019, 32(12): 1386-1389. DOI:10.13200/j.cnki.cjb.002918.
- [12] 张文静, 时念民, 张彦利, 等. 国产 EV71 灭活疫苗上市后大人接种安全性分析[J]. 中国公共卫生, 2019, 035(004): 385-387. DOI:10.11847/zgggws1120234.
Zhang WJ, Shi NM, Zhang YL, et al. Safety analysis of domestic EV71 inactivated vaccine inoculated in large population after marketing[J]. Chin J Public Health, 2019, 35(4):385-387. DOI:10.11847/zgggws1120234.
- [13] 王一军, 潘海燕, 臧霞, 等. 肠道病毒 71 型灭活疫苗 (Vero 细胞) 安全性分析[J]. 公共卫生与预防医学, 2019, 30(1): 16-19. DOI:10.3969/j.issn.1006-2483.2019.01.003.
Wang YJ, Pan HY, Zang X, et al. Safety analysis of inactivated enterovirus 71 vaccine (Vero cells) [J]. Chin J Public Health, 2019, 30(1): 16-19. DOI: 10.3969/j. issn. 1006-2483.2019.01.003.
- [14] 陈玲萍, 孙肖瑜, 魏晶娇, 等. 肠道病毒 71 型灭活疫苗上市后安全性主动与被动监测[J]. 温州医学院学报, 2020, 50(2):149-153. DOI:CNKI:SUN:WZYX.0.2020-02-013.
Chen LP, Sun XY, Wei JJ, et al. Active and passive monitoring of safety of inactivated enterovirus 71 vaccine after marketing[J]. J Wenzhou Med Univ, 2020, 50(2): 149-153. DOI:CNKI:SUN:WZYX.0.2020-02-013.
- [15] Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial [J]. Lancet Infect Dis, 2021, 21(2):181-192. DOI:10.1016/S1473-3099(20)30843-4.
- [16] Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2020, 396(10249):479-488. DOI:10.1016/S0140-6736(20)31605-6.
- [17] Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials[J]. Lancet Infect Dis, 2021, 24: S1473-3099 (21)00127-4. DOI:10.1016/S1473-3099(21)00127-4.